Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epidemiological changes and outcomes of people living with HIV admitted to the intensive care unit: a 14-year retrospective study.
Martínez E, Foncillas A, Téllez A, Fernández S, Martínez-Nadal G, Rico V, Tomé A, Ugarte A, Rinaudo M, Berrocal L, De Lazzari E, Miró JM, Nicolás JM, Mallolas J, De la Mora L, Castro P. Martínez E, et al. Among authors: de la mora l. Infection. 2024 Oct 11. doi: 10.1007/s15010-024-02402-x. Online ahead of print. Infection. 2024. PMID: 39392586
Rapid initiation of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy in HIV infection. A prospective study.
Ugarte A, De La Mora L, De Lazzari E, Chivite I, Fernández E, Inciarte A, Laguno M, Ambrosioni J, Solbes E, Berrocal L, González-Cordón A, Martínez-Rebollar M, Foncillas A, Calvo J, Blanco JL, Martínez E, Mallolas J, Torres B. Ugarte A, et al. Among authors: de la mora l. J Antimicrob Chemother. 2024 Sep 3;79(9):2343-2353. doi: 10.1093/jac/dkae235. J Antimicrob Chemother. 2024. PMID: 39045754 Clinical Trial.
Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV using real-world data: a systematic review and meta-analysis.
Chivite I, Berrocal L, de Lazzari E, Navadeh S, Lluis-Ganella C, Inciarte A, de la Mora L, González-Cordón A, Martínez-Rebollar M, Laguno M, Torres B, Blanco JL, Martínez E, Mallolas J, Ambrosioni J. Chivite I, et al. Among authors: de la mora l. J Antimicrob Chemother. 2024 Aug 1;79(8):1775-1783. doi: 10.1093/jac/dkae138. J Antimicrob Chemother. 2024. PMID: 38758191
Toxic-Induced Encephalopathy Following Chemsex in a Young HIV-Positive Male: A Complex Case of Acute Cognitive Impairment with Anterograde Amnesia and Behavioral Alterations.
Inciarte A, de la Mora L, Huaier-Arriazu E, Torres B, Cañizares S, Zamora E, Laguno M, Gonzalez-Cordón A, Foncillas A, Chivite I, Calvo J, Ambrosioni J, Martínez E, Blanco JL, Miro JM, Martinez-Rebollar M, Mallolas J. Inciarte A, et al. Among authors: de la mora l. Infect Dis Ther. 2024 Apr;13(4):647-658. doi: 10.1007/s40121-024-00962-x. Epub 2024 Apr 3. Infect Dis Ther. 2024. PMID: 38570445 Free PMC article.
Evolving AIDS- and non-AIDS Mortality and Predictors in the PISCIS Cohort of People Living With HIV in Catalonia and the Balearic Islands (Spain), 1998-2020.
Nomah DK, Jamarkattel S, Bruguera A, Moreno-Fornés S, Díaz Y, Alonso L, Aceitón J, Llibre JM, Domingo P, Saumoy M, Homar F, Fanjul F, Navarro J, de la Mora L, Knobel H, Orti A, Martin-Iguacel R, Miró JM, Casabona J, Reyes-Urueña J. Nomah DK, et al. Among authors: de la mora l. Open Forum Infect Dis. 2024 Mar 8;11(4):ofae132. doi: 10.1093/ofid/ofae132. eCollection 2024 Apr. Open Forum Infect Dis. 2024. PMID: 38560603 Free PMC article.
Predictors of poor health-related quality of life among people living with HIV aged ≥60 years in the PISCIS cohort: Findings from the Vive+ project.
Bruguera A, Egea-Cortés L, Mesías-Gazmuri J, Palacio-Vieira J, Forero CG, Miranda C, Saumoy M, Fernández E, Navarro G, Orti A, Miró JM, Casabona J, Reyes-Urueña J; PISCS Study Group. Bruguera A, et al. HIV Med. 2024 Apr;25(4):424-439. doi: 10.1111/hiv.13590. Epub 2023 Dec 13. HIV Med. 2024. PMID: 38092529
Efficacy and safety of raltegravir plus lamivudine maintenance therapy.
Borjabad B, Inciarte A, Chivite I, Gonzalez-Cordon A, Mosquera M, Hurtado C, Rovira C, Gonzalez T, Sempere A, Torres B, Calvo J, De La Mora L, Martinez-Rebollar M, Laguno M, Foncillas A, Ambrosioni J, Blanch J, Rodriguez A, Solbes E, Llobet R, Berrocal L, Mallolas J, Miro JM, Alcami J, Blanco JL, Sanchez-Palomino S, De Lazzari E, Martinez E. Borjabad B, et al. Among authors: de la mora l. J Antimicrob Chemother. 2024 Feb 1;79(2):255-261. doi: 10.1093/jac/dkad364. J Antimicrob Chemother. 2024. PMID: 38039097 Clinical Trial.
Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting.
Rocabert A, Borjabad B, Berrocal L, Blanch J, Inciarte A, Chivite I, Gonzalez-Cordon A, Torres B, Ambrosioni J, Martinez-Rebollar M, Laguno M, De La Mora L, Foncillas A, Sempere A, Rodriguez A, Solbes E, Llobet R, Miro JM, Mallolas J, Blanco JL, De Lazzari E, Martinez E. Rocabert A, et al. Among authors: de la mora l. J Antimicrob Chemother. 2023 Dec 1;78(12):2961-2967. doi: 10.1093/jac/dkad338. J Antimicrob Chemother. 2023. PMID: 37875023
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate for Nonoccupational HIV-1 Postexposure Prophylaxis: A Prospective Open-Label Trial (DORAVIPEP).
Inciarte A, Ugarte A, Martínez-Rebollar M, Torres B, Fernández E, Berrocal L, Laguno M, De la Mora L, De Lazzari E, Callau P, Chivite I, González-Cordón A, Solbes E, Rico V, Barrero L, Blanco JL, Martínez E, Ambrosioni J, Mallolas J; DORAVIPEP Study Group. Inciarte A, et al. Among authors: de la mora l. Open Forum Infect Dis. 2023 Jul 19;10(8):ofad374. doi: 10.1093/ofid/ofad374. eCollection 2023 Aug. Open Forum Infect Dis. 2023. PMID: 37539061 Free PMC article.
51 results